PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annu...(a better understanding of real- wo...),Health

world treatment patterns and clinical outcomes in patients with cancer

receiving chemotherapy and ESA therapy.

Data on PROCRIT in Managed Care Settings

-- Abstract: Drug Utilization Patterns and Cost Considerations for

Erythropoiesis Stimulating Agents in Cancer Chemotherapy Patients in a

Managed Care Setting

Alyson Mandel, Ph.D., Medical Practice Data Corporation, Claverack, NY

Publication Number 5157

A retrospective, observational analysis of ESA utilization in more than

4,100 chemotherapy patients using adjudicated medical claims between

2004 and 2006 from seven health plans was conducted to understand

current utilization patterns. The study examined real-world dosing and

drug costs for ESAs (Epoetin alfa and darbepoetin alfa) in cancer

patients receiving chemotherapy.

-- Abstract: Medical Visit Patterns in Cancer Chemotherapy Patients

Receiving Erythropoiesis Stimulating Agents in a Managed Care Setting

Alyson Mandel, Ph.D., Medical Practice Data Corporation, Claverack, NY

Publication Number 5156

A retrospective analysis of medical claims between January 2004 and

December 2005 using the Integrated Health Care Information Systems

national database and representing more than 35 health plans was

conducted to describe visit patterns and identify the proportion of

medical visits made exclusively for ESA treatment in cancer

chemotherapy patients.

Observational Data from the DOSE Registry

-- Abstract: Hemoglobin Levels Prior To Blood Transfusions In Oncology

Patients Receiving Chemotherapy and Erythropoiesis-Stimulating Agents

(ESAs): Observational Data from the DOSE Registry

Kay Larholt, Sc.D., Abt Associates, Lexington, MA

Publication Number 4019

A retrospective an
'/>"/>